Ivonescimab Monotherapy Demonstrates Significant OS Benefit vs. Pembrolizumab in Phase III HARMONi-2 Study
Summit partner Akeso announced positive overall survival results from the Phase III HARMONi-2 trial in NSCLC. Ivonescimab, licensed for Summit's territories as SMT112, showed statistically significant improvement over pembrolizumab for a key endpoint, reinforcing its potential commercial value.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day